The $550 billion biotech market demands resilient, compliant, and efficient supply chains. Growth is driven by biologics, gene and cell therapies, and personalized medicine, but constrained capital, higher costs, and regulatory complexity make M&A and partnerships critical for scaling R&D and manufacturing. This ETS deck is the full version of our 2026 biotech analysis.
It details the supply chain vulnerabilities that threaten product integrity and patient safety — cold-chain logistics, raw material shortages and single-source dependencies, regulatory compliance, data silos between planning, execution, 3PLs, and CMOs, fill/finish and scale-up constraints, and logistics disruption from freight, customs, geopolitical events, and cost volatility — and the SAP solution for each: SAP Business Network for Logistics with SAP ERP Cloud and EWM for cold-chain excellence, SAP Ariba Supplier Lifecycle and Performance for supplier risk, SAP Advanced Track and Trace for Pharmaceuticals for serialization, SAP IBP with Analytics Cloud for demand visibility, and SAP ERP Cloud with manufacturing execution for batch genealogy and audit readiness.
The roadmap sequences the work from supplier health scoring in the first three months through IBP rollout, ATTP serialization, and logistics network connectivity, with a leadership recommendation to start with supplier resilience and demand/supply visibility. A market section profiles the global biotech leaders, innovation powerhouses, and regional specialists across three impact tiers.
The full deck is available above as a PDF and closes with an executive summary and how ETS delivers SAP solutions for biotech and pharma. For the six-page summary, see the "2026 Biotech Market Snapshot" in the Resource Library.